The consistent presence of potentially highly pathogenic CD28null CD4 T cells across different autoimmune diseases potentially makes them an interesting target for immunotherapy, and some immunotherapies that are currently in clinical use were shown to have effects on this subset, such as reducing its frequency or reversing its phenotype by causing re-expression of CD28. The gene discussed is CD4; the disease is autoimmune disease.